AlphAIAlphAI — Financial news for AI agents
investing.comSEP 81 min read$DOCS

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

Original reporting
investing.com
Published Sep 8, 2026, 4:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DOCS
Bearish
medium confidence
Mentioned
$DOCS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DOCSBearishMed
01

Why it matters

Analyst downgrade reflects concerns over margin compression despite revenue growth.

02

Market read

The downgrade caused a notable intraday price drop, highlighting short‑term risk for traders.

03

What to watch

Potential competitive advantage from early AI search contracts and stabilizing pharma budgets.

Relevance 7/10Novelty 7/10Timing: today

Background

Doximity reported Q1 results beating estimates, raised revenue guidance, but lowered FY2027 EBITDA outlook amid higher AI investment.

Company-level read

Ticker impact

$DOCSBearishMedium confidence
Context

Freedom Capital downgraded Doximity to Hold, cut FY2027 EBITDA guidance and raised price target, triggering a 5.6% share decline.

Expected impact

Potential further short‑term decline of 3‑5% if sentiment remains bearish.

Evidence & confidence

Analyst downgrade with lower EBITDA outlook outweighs modest price‑target increase; market already reacted with a 5.6% drop.

Market effects

Sector

May pressure other health‑tech stocks as AI spend scrutiny intensifies.

Regional

Limited to US tech sector; no broader regional effect.

Global

Minimal global impact beyond U.S. healthcare technology niche.

Counterpoint

What could challenge this read

Price‑target raise could signal longer‑term upside if AI initiatives gain traction.

Key entities

  • analyst
    Freedom Capital

    Equity research firm issuing the downgrade.

Read at source← All news

Related articles

SEP 14
MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

finance.yahoo.com2 min
AUG 16
$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

aol.com6 min
AUG 14
$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.

fool.com7 min
AUG 11
$DOCSMed

Doximity Stock Surges in Overnight Trading as Chief Executive Highlights High-Margin AI Tool

Doximity (DOCS) shares jumped in overnight trading after CEO Jeffrey Tangney said the company’s new AI search tool generates over 10 times the revenue versus its operating cost. The stock later closed up 33% on Friday. Doximity reported Q1 revenue of $156.6M and adjusted EBITDA of $74.8M, and raised full-year guidance to $671M-$681M. Wells Fargo later downgraded to underweight.

tikr.com6 min
AUG 11
$DOCSMedAI 8/10

DOCS Q2 Deep Dive: AI Product Adoption Fuels Revenue Growth, Margins Face Investment Pressures

Doximity reported Q2 revenue of $156.6M, up 7.3% year over year and above analysts’ $151.3M estimate. Adjusted EBITDA was $74.77M versus $69.59M, but adjusted EPS was $0.29 versus $0.30. The company slightly lifted full-year revenue guidance to $676M midpoint, while EBITDA guidance of $319M trails estimates. Management cited AI product adoption and NOHARM study validation, alongside higher AI investment pressuring margins.

finance.yahoo.com7 min